Clinical study on Zhijiangning Tablets combined with evolocumab in treatment of statin intolerance hyperlipidemia
Objective To explore the clinical effect of Zhijiangning Tablets combined with evolocumab in treatment of statin intolerance hyperlipidemia.Methods Patients(124 cases)with statin intolerance hyperlipidemia in Affiliated Zhongshan Hospital Dalian University from July 2021 to July 2023 were randomly divided into control(62 cases)and treatment(62 cases)group.Patients in the control group were hypodermic injection administered with Evolocumab Injection,140 mg/time,once every 15 d.Patients in the treatment group were po administered with Zhijiangning Tablets on the basis of the control group,4 tablets/time,three times daily.Patients in two groups were treated for 8 weeks.After treatment,the clinical evaluations were evaluated,the symptom relief time,and the levels of serum TC,TG,LDL-C,HDL-C,ET-1,IL-6,P-selectin and TNF-α in two groups before and after treatment were compared.Results After treatment,the clinical effective rate of the treatment group was 95.16%,which was significantly higher than that of the control group(83.87%,P<0.05).After treatment,the time of symptom improvement in the treatment group was significantly earlier than that in the control group(P<0.05).After treatment,the levels of TC,TG and LDL-C in two groups were significantly lower than those before treatment,while HDL-C was significantly increased(P<0.05),and the blood lipid level in the treatment group was significantly better than that in the control group(P<0.05).After treatment,the serum levels of ET-1,IL-6,P-selectin and TNF-α were significantly decreased in two groups,which in the treatment group were significantly lower than that in the control group(P<0.05).Conclusion The synergistic treatment of Evolocumab Injection and Zhijiangning Tablets can effectively improve the symptoms of patients with hyperlipidemia,better regulate the content of blood lipids and reduce the inflammatory reaction in vivo.
NETL
NSTL
万方数据
